A Novel MHCp Binding Prediction Model

Human Immunology

Volumn 64, Issue 12, 2003, Pages 1123-1143

  Zhao, Bing ^a   Mathura, Venkatarajan Subramanian ^b   Rajaseger, Ganapathy ^c   Moochhala, Shabbir ^c   Sakharkar, Meena Kishore ^a   Kangueane, Pandjassarame ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Def Med Research Institute #20 04   (Singapore)

Author keywords

Amino acids; MHC; Peptide binding; Prediction; Property matrix

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE;

ACCURACY; ALLELE; ANTIGEN BINDING; ARTICLE; IC 50; PREDICTION; PRIORITY JOURNAL; STATISTICAL MODEL; VALIDATION PROCESS;

EID: 0344420229     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2003.08.343     Document Type: Article

References (102)

1. Sliz P, Michielin O, Cerottini JC, Luescher I, Romero P, Karplus M, Wiley DC: Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol 167:3276, 2001.
2. Zhao R, Loftus DJ, Appella E, Collins EJ: Structural evidence of T cell xeno-reactivity in the absence of molecular mimicry. J Exp Med 189:359, 1999.
3. Buslepp J, Zhao R, Donnini D, Loftus D, Saad M, Appella E, Collins EJ: T cell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surface. J Biol Chem 276:47320, 2001.
4. Kirksey TJ, Pogue-Caley RR, Frelinger JA, Collins EJ: The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class-I major histocompatibility complexes. J Biol Chem 274:37259, 1999.
5. Madden DR, Garboczi DN, Wiley DC: The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75:693, 1993.
6. Gao GF, Tormo J, Gerth UC, Wyer JR, McMichael AJ, Stuart DI, Bell JI, Jones EY, Jakobsen BK: Crystal structure of the complex between human CD8alpha (alpha) and HLA-A2. Nature 387:630, 1997.
7. Ding YH, Baker BM, Garboczi DN, Biddison WE, Wiley DC: Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 11:45, 1999.
8. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC: Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134, 1996.
9. Ding YH, Smith KJ, Garboczi DN, Utz U, Biddison WE, Wiley DC: Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/tax peptide complex using different TCR amino acids. Immunity 8:403, 1998.
10. Khan AR, Baker BM, Ghosh P, Biddison WE, Wiley DC: The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. J Immunol 164:6398, 2000.
11. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL, Wiley DC: Antigen presentation subverted: structure of the human cytomegalovirus protein Us2 bound to the class I molecule HLA-A2. Proc Nat Acad Sci USA 98:6794, 2001.
12. Madden DR, Gorga JC, Strominger JL, Wiley DC: The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggest a general mechanism for tight peptide binding to MHC. Cell 70:1035, 1992.
13. Hulsmeyer M, Hillig RC, Volz A, Ruhl M, Schroder W, Saenger W, Ziegler A, Uchanska-Ziegler B: HLA-B27 subtypes differentially associated with disease exhibit subtle structural alterations. J Biol Chem 277:47844, 2002.
14. Menssen R, Orth P, Ziegler A, Saenger W: Decamer-like conformation of a nona-peptide bound to HLA-B*3501 due to non-standard positioning of the C terminus. J Mol Biol 285:645, 1999.
15. Maenaka K, Maenaka T, Tomiyama H, Takiguchi M, Stuart DI, Jones EY: Non-standard peptide binding revealed by crystal structures of HLA-B*5101 complexed with HIV immunodominant epitopes. J Immunol 165:3260, 2000.
16. Smith KJ, Reid SW, Harlos K, McMichael AJ, Stuart DI, Bell JI, Jones EY: Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53. Immunity 4:215, 1996.
17. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD: Structure of an NK cell immunoglobulin-like receptor in complex with its class-I MHC ligand. Nature 405:537, 2000.
18. Fan QR, Long EO, Wiley DC: Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2:452, 2001.
19. Alexander J, Del Guercio MF, Fikes JD, Chesnut RW, Chisari FV, Chang KM, Appella E, Sette A: Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Hum Immunol 59:776, 1998.
20. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E: Multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1, 1998.
21. Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chisari FV, Sette A: Identification of HLA-A3 and HLA-B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 162:1156, 1999.
22. Bashin M, Singh H, Raghava PS: MHCBN: a comprehensive database of MHC binding and non-binding peptides. Bioinformatics 19:665, 2003.
23. Blythe MJ, Doytchinova IA, Flower DR: JenPep: a database of quantitative functional peptide data for immunology. Bioinformatics 18:434, 2002.
24. Joshi RV, Zarutskie JA, Stern LJ: A three-step kinetic mechanism for peptide binding to MHC class II proteins. Biochemistry 39:3751, 2000.
25. Kasson PM, Rabinowitz JD, Schmitt L, Davis MM, McConnell HM: Kinetics of peptide binding to the class II MHC protein I-Ek. Biochemistry 39:1048, 2000.
26. Natarajan SK, Assadi M, Sadegh-Nasseri S: Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J Immunol 162:4030, 1999.
27. Springer S, Doring K, Skipper JC, Townsend AR, Cerundolo V: Fast association rates suggest a conformational change in the MHC class I molecule H-2Db upon peptide binding. Biochemistry 37:3001, 1998.
28. Reiser JB, Gregoire C, Darnault C, Mosser T, Guimezanes A, Schmitt-Verhulst AM, Fontecilla-Camps JC, Mazza G, Malissen B, Housset D: A T-cell receptor CDR3 beta loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide/MHC class I complex. Immunity 16:345, 2002.
29. Reiser JB, Darnault C, Guimezanes A, Gregoire C, Mosser T, Schmitt-Verhulst AM, Fontecilla-Camps JC, Malissen B, Housset D, Mazza G: Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nat Immunol 1:291, 2000.
30. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA: A functional hot spot for antigen recognition in a super agonist TCR/MHC complex. Immunity 12:251, 2000.
31. Luz JG, Huang M, Garcia KC, Rudolph MG, Apostolopoulos V, Teyton L, Wilson IA: Structural comparison of allogeneic and syngeneic T cell. receptor-pepride major histocompatibility complex complexes: a buried alloreactive mutation subtly alters peptide presentation substantially increasing V(beta) Interactions. J Exp Med 195:1175, 2002.
32. Garcia KC, Degano M, Pease LR, Huang M, Peterson PA, Teyton L, Wilson IA: Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 279:1166, 1998.
33. Hennecke J, Carfi A, Wiley DC: Structure of a covalently stabilized complex of a human alpha beta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J 19:5611, 2000.
34. Hennecke J, Wiley DC: Structure of a complex of the human alpha/beta T cell receptor (TCR) Ha17, Influenza hemagglutinin peptide, and major histocompatibility complex class II molecule: HLA-DR4 (DRA*0101 and DRB*10401). Insight into TCR cross-restriction and alloreactivity. J Exp Med 195:571, 2002.
35. Reinherz EL, Tan K, Tang L, Kern P, Liu J, Xiong Y, Hussey RE, Smolyar A, Hare B, Zhang R, Joachimiak A, Chang HC, Wagner G, Wang J: The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286:1913, 1999.
36. Altman JD, Moss PAH, Goulder PJR, Barouch DH, Mcheyzer-Williams MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of antigen specific T lymphocytes. Science 274:94, 1996.
37. Aubert G, Hassan-Walker AF, Madrigal JA, Emery VC, Morte C, Grace S, Koh MB, Potter M, Prentice HG, Dodi IA, Travers PJ: Cytomegalovirus specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 184:955, 2001.
38. Prezzi C, Casciaro MA, Francavilla V, Schiaffella E, Finocchi L, Chircu LV, Bruno G, Sette A, Abrignani S, Barnaba V: Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 31:894, 2001.
39. Bonelo A, Valmori D, Triponez F, Tiercy JM, Mentha G, Oberholzer J, Champagne P, Romero JF, Esposito F, Nebie I, Barbey C, Romero P, Herrera S, Corradin G, Lopez JA: Generation and characterization of malaria specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentation by liver cells. Eur J Immunol 30:3079, 2000.
40. Grabowska AM, Lechner F, Klenerman P, Tighe PJ, Ryder S, Ball JK, Thomson BJ, Irving WL, Robin RA: Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 31:2388, 2001.
41. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD: Antibodies to the junctional adhesion molecule cause disruption of endothelial cells and do not prevent leukocyte influx into the meninges after viral or bacterial infection. J Exp Med 191:1499, 2000.
42. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL: HIV specific CD8 (+) T cells produce antiviral cytokines but are impaired in cyrolytic function. J Exp Med 192:63, 2000.
43. Catalina MD, Sullivan JL, Bak KR, Luzuriaga K: Differential evolution and stability of epitope specific CD8 (+) T cell responses in EBV infection. J Immunol 167:4450, 2001.
44. Faint JM, Annels NE, Curnow SJ, Shields P, Pilling D, Hislop AD, Wu L, Akbar AN, Buckley CD, Moss PA, Adams DH, Rickinson AB, Salmon M: Memory T cells constitute a subset of the human CD8+ CD45 RA+ pool with distinct phenotypic and migratory characteristics. J Immunol 167:212, 2001.
45. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB: Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein Barr virus infection. J Exp Med 195:893, 2002.
46. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C: Lamivudine treatment can overcome cytotoxic T cell hypo-responsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963, 2001.
47. Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, Dusheiko G, Williams R, Maini MK, Bertoletti A: Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 195:1089, 2002.
48. Kim SK, Devine L, Angevine M, DeMars R, Kavathas PB: Direct detection and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific CD8+ CTLs with HLA class I tetramers. J Immunol 165:7285, 2000.
49. Vaz Santiago J, Lule J, Rohrlich P, Jacquier C, Gibert N, Le Roy E, Betbeder D, Davignon JL, Davrinche C: Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus sero-positive blood donors by using a soluble recombinant chimeric protein, IE1-pp65. J Virol 75:7840, 2001.
50. Hassan-Walker AF, Vargas Cuero AL, Mattes FM, Klenerman P, Lechner F, Burroughs AK, Griffiths PD, Phillips RE, Emery VC: CD8+ cytotoxic lymphocyte responses against cytomegalovirus after liver transplantation: correlation with time from transplant to receipt of tacrolimus. J Infect Dis 183:835, 2001.
51. Ogg GS, Kostense S, Klein MR, Jurriaans S, Hamann D, McMichael AJ, Miedema F: Longitudinal phenotypic analysis of human immunodeficiency virus type-1 specific cytotoxic T lymphocytes: correlation with disease progression. J Virol 73:9153, 1999.
52. Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P, Lieberman J: Longitudinal phenotypic analysis of human immunodeficiency virus type-1 specific cytotoxic T lymphocytes: correlation with disease progression. Blood 96:3094, 2000.
53. Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J: Human immunodeficiency virus specific circulating CD8(+) T lymphocytes have down modulated CD3 zeta and CD28, key signaling molecules for T-cell activation. J Virol 74:7320, 2000.
54. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M: HLA-B*5701 is highly associated with restriction of virus replication in a subgroup of HIV infected long term non-progressors. Proc Natl Acad Sci USA 97:2709, 2000.
55. Kostense S, Ogg GS, Manting EH, Gillespie G, Joling J, Vandenberghe K, Veenhof EZ, van Baarle D, Jurriaans S, Klein MR, Miedema F: High viral burden in the presence of major HIV specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol 31:677, 2001.
56. Seth A, Markee J, Hoering A, Sevin A, Sabath DE, Schmitz JE, Kuroda MJ, Lifton MA, Hirsch MS, Collier AC, Letvin NL, McElrath MJ: Alterations in T cell phenotype and human immunodeficiency virus type-1 specific cycotoxicity after potent anti-retroviral therapy. J Infect Dis 183:722, 2001.
57. Rinaldo CR Jr, Huang XL, Fan Z, Margolick JB, Borowski L, Hoji A, Kalinyak C, McMahon DK, Riddler SA, Hildebrand WH, Day RB, Mellors JW: Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination anti-retroviral therapy in HIV-1 infected patients with advanced immunodeficiency. J Virol 74:4127, 2000.
58. Sobao Y, Tomiyama H, Nakamura S, Sekihara H, Tanaka K, Takiguchi M: Visual demonstration of hepatitis C virus specific memory CD8(+) T-cell expansion in patients with acute hepatitis C. Hepatology 33:287, 2001.
59. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ: Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103, 1998.
60. Kaul R, Rowland-Jones SL, Gillespie G, Kimani J, Dong T, Kiama P, Simonsen JN, Bwayo JJ, McMichael AJ, Plummer FA: Gonococcal cervicitis is associated with reduced systemic CD8+ T cell responses in human immunodeficiency virus type-1 infected and exposed: uninfected sex workers. J Infect Dis 185:1525, 2002.
61. Kuon W, Holzhutter HG, Appel H, Grolms M, Kollnberger S, Traeder A, Henklein P, Weiss E, Thiel A, Lauster R, Bowness P, Radbruch A, Kloetzel PM, Sieper J: Identification of HLA-B27 restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27 associated diseases. J Immunol 167:4738, 2001.
62. Dorrell L, Willcox BE, Jones EY, Gillespie G, Njai H, Sabally S, Jaye A, DeGleria K, Rostron T, Lepin E, McMichael A, Whittle H, Rowland-Jones S: Cytotoxic T lymphocytes recognize structurally diverse: clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53. Eur J Immunol 31:1747, 2001.
63. 51Cr labelled allogeneic target cells in vitro: inhibition by isoantibody and by drugs. Immunology 14:181, 1968.
64. Cerottini JC, Brunner KT: Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol 18:67, 1974.
65. Feltkamp MC, Vierboom MP, Kast WM, Melief CJ: Efficient MHC class-I peptide binding is required but does not ensure MHC class-I restricted immunogenicity. Mol Immunol 31:1391, 1994.
66. Lawson TM, Man S, Wang EC, Williams S, Amos N, Gillespie GM, Moss PA, Borysiewicz LK: Functional differences between influenza A specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. Int Immunol 13:1383, 2001.
67. http.//www.ebi.ac.uk/imgt/hla
68. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ, Stoehr P, Marsh SGE: IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 31:311, 2003.
69. Hammer J, Takacs B, Sinigaglia F: Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 176:1007, 1992.
70. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F: Precise prediction of major histocompatibility complex class II peptide interaction based on peptide side chain scanning. J Exp Med 180:2353, 1994.
71. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U: Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555, 1999.
72. Singh H, Raghava GPs: ProPred: prediction of HLA-DR binding sites. Bioinformatics 17:1236, 2001.
73. Singh H, Raghava GPs: ProPredl: prediction of promiscuous MHC class-I binding sites. Bioinformatics 19:1009, 2003.
74. Parker KC, Bednarek MA, Coligan. JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163, 1994.
75. Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S: SYFPEITHI: atabase for MHC ligands and peptide motifs. Immunogenetics 50:213, 1999.
76. Guan PP, Doytchinova IA, Flower DR: HLA-A3 supermotif defined by quantitative structure-activity relationship analysis. Protein Eng 16:11, 2003.
77. Doytchinova IA, Flower DR: Toward the quantitative prediction of T-cell epitopes: coMFA and coMSIA studies of peptides with affinity for the class-I MHC molecule HLA-A*0201. J Med Chem 44:3572, 2001.
78. Doytchinova IA, Blythe MJ, Flower DR: Additive method for the prediction of protein-peptide binding affinity. Application to the MHC class I molecule HLA-A*0201. J Proteome Res 1:263, 2002.
79. Brusic V, Rudy G, Honeyman MC, Hammer J, Harrison LC: Prediction of MHC class-II binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 14:121, 1998.
80. Honeyman MC, Brusic V, Stone N, Harrison LC: Neutral network based prediction of candidate T-cell epitope. Nat Biotechnol 16:966, 1998.
81. Mamitsuka H: Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Proteins 33:460, 1998.
82. Dönnes P, Elofsson A: Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 3:25, 2002.
83. Schueler-Furman O, Elber R, Margalit H: Knowledge-based structure prediction of MHC class I bound peptides: a study of 23 complexes. Fold Des 3:549, 1998.
84. Schueler-Furman O, Altuvia Y, Sette A, Margalit H: Structure-based prediction of binding peptides to MHC class I molecules: application to a broad range of MHC alleles. Protein Sci 9:1838, 2000.
85. Rognan D, Lauemoller SL, Holm A, Buus S, Tschinke V: Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins. J Med Chem 42:4650, 1999.
86. Kangueane P, Sakharkar MK, Lim KS, Hao H, Lin K, Chee RE, Kolatkar PR: Knowledge-based grouping of modeled HLA peptide complexes. Hum Immunol 61:460, 2000.
87. Lee C, McConnell HM: A general model of invariant chain association with class II major histocompatibility complex proteins. Proc Natl Acad Sci USA 92:8269, 1995.
88. Altuvia Y, Schueler O, Margalit H: Ranking potential binding peptides to MHC molecules by a computational threading approach. J Mol Biol 249:244, 1995.
89. Altuvia Y, Sette A, Sidney J, Southwood S, Margalit H: A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets. Hum Immunol 58:1, 1997.
90. Rognan D, Scapozza L, Folkers G, Daser A: Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T cell epitopes. Biochemistry 33:11476, 1994.
91. Kangueane P, Sakharkar MK, Kolatkar PR, Ren EC: Towards the MHC-peptide combinatorics. Hum Immunol 62:539, 2001.
92. Abagyan RA, Batalov S: Do aligned sequences share the same fold? J Mol Biol 273:355, 1997.
93. Adrian P, Rajaseger G, Mathura V, Sakharkar M, Kangueane P: Types of inter-atomic interactions at the MHC-peptide interface: identifying commonality from accumulated data. BMC Struct Biol 2:2, 2002.
94. Miyazawa S, Jernigan RL: Estimation of effective interresidue contact energies from protein crystal structure, quasi-chemical approximation. Macromolecules 18:534, 1985.
95. Miyazawa S, Jernigan RL: Residue-residue potentials with a favorable contact pair term and an unfavorable high packing density term, for simulation and threading. J Mol Biol 256:623, 1996.
96. Govindarajan KR, Kangueane P, Tan TW, Ranganathan S: MPID: MHC-peptide interaction database for sequence structure function information on peptides binding to MHC molecules. Bioinformatics 19:309, 2003.
97. Ren EC, Kangueane P, Kolatkar P, Lin MT, Tseng LH, Hansen JA: Molecular modeling of the minor histocompatibility antigen HA-1 peptides binding to HLA-A alleles. Tissue Antigens 55:24, 2000.
98. Zhao B, Png AEH, Ren EC, Kolatkar PR, Mathura VS, Sakharkar MK, Kangueane P: Compression of functional space in HLA-A sequence diversity. Hum Immunol 64:718, 2003.
99. Chelvanayagam G: A roadmap for HLA-A, HLA-B and HLA-C peptide binding specificities. Immunogenetics 45:15, 1996.
100. Chelvanayagam G: A roadmap for HLA-DR peptide binding specificities. Hum Immunol 58:61, 1997.
101. Zhang C, Anderson A, DeLisi C: Structural principles that govern the peptide binding motifs of class I MHC molecules. J Mol Biol 281:929, 1998.
102. Venkatarajan MS, Braun W: New quantitative descriptor of amino acids based on multi-dimensional scaling of a large number of physical-chemical properties. J Mol Model 7:445, 2001.